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Abstract We previously found that the promoter activity of
plasminogen (PLG)-related gene B (PRGB) was 5-fold that of
PLG. We have since examined the transcript levels of PRGB
among various normal human tissues, and compared these
findings with those of PLG. Reverse transcription-PCR analysis
revealed that the PRGB expression varied widely among
different tissues, while PLG was expressed only in the liver and
kidney. RNA samples obtained from cultured cell lines also
demonstrated differing PRGB expression. Furthermore, in-
creased PRGB expression was observed in several fresh samples
of cancer tissue obtained from cancer patients when compared
with surrounding normal tissues.
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1. Introduction
Plasminogen (PLG) is a key proenzyme of plasmin in the
¢brinolytic and thrombolytic systems. Cleavage at the Arg-
561^Val-562 bond in PLG by tissue PLG activator or urokin-
ase results in the formation of a serine protease plasmin.
Plasmin also plays an important role in processes which in-
volve the breakdown of extracellular matrices, such as tumor
cell migration, angiogenesis, and neurodevelopment [1^3].
During the course of previous studies to characterize nor-
mal and abnormal PLG genes [4^6], we identi¢ed new genes
homologous to that for PLG, including PLG-related genes A,
B, and C (designated PRGA, PRGB, and PRGC, respec-
tively). These genes belong to the PLG-apolipoprotein (a)
gene family [7,8]. The gene products of PRGA and PRGB
are expected to be polypeptides of 8.8 kDa that correspond
only to the preactivation peptide (PAP) domain of PLG. This
domain plays an essential role in the conversion of the ‘acti-
vation-resistant’ conformation of native PLG to its ‘activa-
tion-ready’ form [9]. It is of interest that PRGB is expressed
in the liver and, most prominently, in metastatic cancer cells
[10]. Apart from the presence of transcripts of these PRGs,
functions of their possible gene products remain unknown to
date.
Since PLG and PRGs share an extremely high degree of
sequence identity [7], these genes may be coordinately ex-
pressed; moreover, similar transcription factors may control
both genes. In order to understand the expression of PRGA
and PRGB, we ¢rst studied the transcriptional regulation of
these genes [11]. The sequences of the 5P-£anking regions of
PRGA and PRGB were established and their transcriptional
activity was demonstrated to be largely dependent on a region
surrounding the transcription initiation site of PLG [12]. In
the present study we examine transcript levels for PRGB in
various normal and tumor tissues and transformed cells, and
demonstrate that it was expressed at increased levels in fresh
cancer tissues.
2. Materials and methods
Venous blood was drawn from normal individuals and patients
with blood dyscrasia. Tissues were obtained from patients with a
tumor (or cancer) after informed consent had been obtained. These
include nine bladder carcinoma (four at stage II and ¢ve at stage III),
three renal cell carcinoma (one each for stage I, II, and IIIc), three
stage II breast carcinoma (two papillotubular carcinoma, one solid
tubular carcinoma), one gastric adeno-carcinoma (Borrman I), one
ovarian carcinoma (stage Ia mucinous adeno-carcinoma), three stage
I lung carcinoma (one each of small cell carcinoma, squamous carci-
noma, and adeno-carcinoma), one colon carcinoma (stage I adeno-
carcinoma, Rb at lower rectum), thyroid adenoma, one thymoma
(hyperplasia), one stage IV malignant lymphoma (non-Hodgkin, dif-
fuse lymphoblastic T-cell type), acute promyelocytic leukemia [APL,
t(15:17)], and chronic myelocytic leukemia (CML, blastic crisis). The
tissues collected during surgery were frozen immediately in liquid
nitrogen and stored at 380‡C until use.
2.1. RT and PCR analyses for screening
Total RNA was extracted by the standard guanidinium thiocyanate
method from various samples, followed by ultracentrifugation on a
cesium chloride gradient. Reverse transcription (RT) of the total
RNA (10 mg) was carried out using random hexanucleotides or an
oligo dT (dT18) primer and Superscript II RNase H-reverse transcrip-
tase (Gibco-BRL, Gaithersburg, MD). The synthesized ¢rst-strand
cDNA was used for PCR in a reaction mixture of 50 ml by employing
various pairs of primers for PLG or PRGB (Fig. 1); for PLG, 5P-
AAGCAGCTGGGAGCAGGAAGTAT-3P (PAP-S1 sense), and 5P-
GTCTAAGCTTCTGCAGTAGTTCTCCTCCAGTC-3P (K1b-AS3,
antisense); for PRGB, 5P-ACTATGTGAATACCCAGGGGC-3P
(PRGB5 sense), and 5P-ATACATTTACTTTTCAAATAAAACGT-
3P (PRGB3 antisense); for human glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) as an internal control, 5P-CATCACCATCTTC-
CAGGAGC-3P (sense) and 5P-TAAGCAGTTGGTGGTGCAGG-3P
(antisense). After 30 cycles (for PLG and PRGB) or 23 cycles (for
GAPDH), 10 ml of the reaction mixture was applied to a 2.0% agar-
ose gel, followed by staining with ethidium bromide. The gel was
subjected to quantitation of the ampli¢ed products by FLA-2000 Flu-
oroimage Analyzer (Fuji Photo Film, Tokyo, Japan). The £uorescence
intensity of the PCR products for PRGB and PLG was normalized to
that for GAPDH. When necessary, the expression levels of PRGB and
PLG were then graded as follows: the value of PRGB or PLG/
GAPDH in the liver sample was de¢ned as 1.0; ‘3’ 6 0.13;
0.139 ‘ þ ’6 0.25; 0.25 = ‘+’6 0.5; 0.59 ‘++’.
RT-PCR analysis was carried out employing total RNA isolated
from various normal tissues, tumor tissues and cultured cell lines in
the following experiments, three times for each sample.
FEBS 21565 19-2-99
0014-5793/99/$19.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 0 9 3 - 9
*Corresponding author. Fax: (81) (23) 628-5280.
E-mail: aichinos@med.id.yamagata-u.ac.jp
Abbreviations: PAP, preactivation peptide; PLG, plasminogen; PRG,
plasminogen-related gene; RT, reverse transcription
FEBS 21565 FEBS Letters 445 (1999) 31^35
2.2. Sequence analysis
DNA sequences of RT-PCR products were obtained using the di-
deoxy termination method with ABI sequence analyzer 373A (Perkin-
Elmer, Norwalk, CT). Sequence homology searches for the DNA
fragments were performed by using the BLAST Network Service in
GenBank, in order to identify the PRGB gene and to con¢rm the
exclusion of possible co-ampli¢cation of other homologous genes.
2.3. Semi-quantitative RT-PCR for PRGB in normal and cancer
tissues
Using serially diluted samples of the synthesized ¢rst-strand cDNA,
semi-quantitative RT-PCR was carried out by employing 3.7U1032
MBq of [K-35S]dCTP and the proper primers in a reaction mixture of
25 Wl. After 30 cycles (for PRGB) or 23 cycles (for GAPDH), 10 ml of
the reaction mixture was applied to a 9.0% polyacrylamide gel. The
gel was then subjected to quantitation of the ampli¢ed products by
FLA-2000 Fluoroimage Analyzer. The radioactivity of the PCR prod-
uct for PRGB or PLG was normalized to that for GAPDH. Tran-
script levels of PRGB in normal and cancer tissues were compared
using their diluted samples, which showed a linear relationship be-
tween the amounts of total RNA used and the £uorescent intensity
of the radioactive bands.
2.4. Cell culture
All human cell lines were obtained from the Japanese Cancer Re-
search Resources Bank except for HUVEC (human umbilical vein
endothelial cells), which was the kind gift of Prof. Y. Sato at Tohoku
University. A-172 (glioblastoma), A549 (alveolar carcinoma), G-292,
HOS and MG-63 (osteosarcoma), HeLa AG (cervical carcinoma),
HepG2 and Huh-7 (hepatoma), HL-60 and HLG (acute promyelo-
cytic leukemia), HUVEC, MEG01 (megakaryoblastic leukemia), Mit-
en and SF-TY (¢broblast), NEC8 (testicular germ cell tumor), SCH
(gastric cancer) and U937 (monocytic leukemia) cells were maintained
either in Dulbecco’s modi¢ed Eagle’s medium, RPMI 1640, or Eagle’s
minimal essential medium (Nikken Biomedical Laboratory, Tokyo,
Japan), supplemented with 10% fetal bovine serum (SEBAK
GmbH, Germany), 50 mg/ml penicillin, 50 mg/ml streptomycin, and
100 mg/ml neomycin (PSN Antibiotic Mixture, Gibco-BRL).
3. Results and discussion
3.1. Selective ampli¢cation of PRGB
The organization of human PRGB, in terms of the loca-
tions of introns (Fig. 1) and the types of splice junctions, was
identical to the gene encoding PLG [7]. The PRGB and PLG
genes share more than 95% sequence identity. In order to
distinguish PRGB mRNA from those for other members of
the PLG-apo(A) gene family, especially PLG and PRGA, we
designed a pair of gene-speci¢c oligonucleotide primers for
PRGB as described in Section 2. Using this primer pair we
established the PCR condition for ampli¢cation of PRGB
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Fig. 1. Nucleotide sequence of a part of the gene and cDNA for PLG (top line) and PRGB (bottom line). Nucleotides identical in both PRGB
and PLG are shown by asterisks. The arrows represent gene-speci¢c primer pairs for PRGB and PLG, which are labeled at their 5P ends. Short
vertical arrows indicate the positions of introns. 5P-NC, 5P-noncoding region; signal, signal peptide; PAP1, 1st half of preactivation peptide;
PAP2, 2nd half of PAP; K1a, 1st half of Kringle 1; K1b, 2nd half of Kringle 1.
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alone. Sequencing analysis together with a computer-assisted
homology search con¢rmed that PRGB was speci¢cally am-
pli¢ed by the current method: no genes homologous to PRGB
were identi¢ed in the ampli¢ed products. Speci¢c ampli¢ca-
tion of PRGB was also con¢rmed by restriction fragment
length polymorphism (RFLP) analysis with EarI (data not
shown), since an EarI site is present only in PRGB but not
in PRGA or PLG. In addition, we established the PCR con-
ditions necessary for ampli¢cation of PLG alone. Speci¢c am-
pli¢cation of PLG was con¢rmed by sequencing analysis and
digestion with EarI and MboII, since two MboII sites exist in
PLG and PRGB, while only one is found in PRGA.
3.2. Di¡ering in vivo expression of PRGB in various normal
tissues
In order to identify the site of PRGB expression in vivo, we
screened a number of tissues and organs by RT-PCR using
PRGB-speci¢c primers. DNA bands were observed for vari-
ous normal human tissues. Selected results are demonstrated
in Fig. 2. When we graded the expression levels of PRGB by
scoring the £uorescence intensity of its DNA bands, adult
liver, fetal liver, and prostate scored ‘++’ (Fig. 2, top), while
stomach scored ‘3’ (Table 1). The scores of many other or-
gans/tissues ranged from ‘+’ to ‘ þ ’. Although Weissbach and
Treadwell reported that no PRGB mRNA was detected in
normal breast tissue [10], our results clearly demonstrated
the presence of PRGB mRNA in the sample isolated from a
healthy (normal) breast. This may be due to the di¡erence in
sensitivity of the methods employed in both studies. It was
found for the ¢rst time that PRGB expression varies widely
among normal extrahepatic tissues, while GAPDH mRNA is
ubiquitously expressed. In contrast to PRGB, PLG was ex-
pressed only in the liver and kidney (Fig. 2, bottom). These
results suggest that although the PRGB and PLG genes are
highly homologous [7], their gene regulation di¡ers markedly
[11].
It is interesting that the prostate obtained from two indi-
viduals scored ‘++’, while that obtained from a third scored
‘ þ ’ (Table 1), indicating the presence of a deviation in PRGB
expression among individuals. However, no signi¢cant di¡er-
ence in PRGB mRNA levels was observed in other tissues,
including the liver, breast and kidney (described later).
In contrast to PRGB and PLG, judging from the PCR-
RFLP pattern the PRGA transcript was undetectable in all
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Fig. 2. Expression of PRGB (top) and PLG (bottom) detected by
RT-PCR. The expression levels of PRGB and PLG are relatively
graded as described in Section 2. Each tissue was examined three
times by the method as described in Section 2.
Table 1
Detection of mRNAs for PRGB and PLG in normal organs and tissues
Organ/tissue PRGB PLG Organ/tissue PRGB PLG
Brain (cortex) + 3 Spleen + 3
Tonsil þ 3 Kidney + +
Thyroid + 3 Ovary + 3
Thymus + 3 Uterus + 3
Lung + 3 Prostate þ ^++ 3
Cardiac muscle + 3 Testis þ 3
Breast + 3 Placenta + 3
Pancreas + 3 Bladder þ 3
Liver ++ ++ Skeletal muscle þ 3
Fetal liver ++ ++ Leukocytes + 3
Stomach 3 3
PRGB or PLG/GAPDH in the liver, 1.0; ‘3’ 6 0.13; 0.139 ‘ þ ’6 0.25; 0.259 ‘+’6 0.5; 0.59 ‘++’. Each tissue was examined three times by the
method as described in Section 2.
Table 2
Detection of mRNAs for PRGB and PLG in cultured cell lines
Cell line PRGB PLG Cell line PRGB PLG
A-172 þ 3 HL-60 þ 3
A549 þ 3 HLG þ 3
G-292 + 3 HUVEC þ 3
HOS þ 3 MEG01 + 3
MG-63 + 3 Miten þ 3
HeLa AG 3 3 NEC8 3 3
HepG2 + + SCH 3 3
Huh-7 þ + U-937 þ 3
Ca, carcinoma; A-172, glioblastoma; A549, alveolar cell ca; G-292,
HOS, MG-63, osteosarcoma; HeLa AG, cevical ca; HepG2, hepato-
cellular ca; Huh7, hepatoma; HL-60, HLG, promyelocytic leukemia;
HUVEC, umbilical vein endothelial cell ; MEG01, megakaryoblastic
leukemia; Miten, ¢broblast; NEC8, testicular teratoma; SCH, gastric
cancer; SF-TY, ¢broblast; U-937, histiocytic lymphoma. Each tissue
was examined three times.
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tissue samples including the liver examined in the present
study (Tateno and Ichinose, unpublished data).
3.3. Expression of PRGB in transformed cell lines
We also screened for the transcripts of PRGB and PLG in
various transformed cell lines by RT-PCR employing the
same conditions as used to examine normal tissues/organs
(Fig. 2). The PRGB transcript was observed in osteosarcoma
cell lines (G-292, MG-63 and HOS in Table 2), a ¢nding
consistent with the report that PRGB expression was detected
in MG-63 [10]. It was of interest that PRGB expression in a
megakaryoblastic leukemia cell line (MEG01) was relatively
high. In contrast, PLG was expressed only in hepatoma cell
lines (HepG2 and Huh-7); its mRNA was not detected in any
other cultured cell lines. These results are in good agreement
with the fact that a high expression level of PLG was found
only in the liver and kidney, as described in the preceding
section. Thus, it may be said that since the expression activity
of PRGB is much higher than that of PLG [11], PRGB can be
transcribed e⁄ciently in various tissues and cell lines. The
liver must be very rich in transcription factors which drive a
relatively weak PLG promoter. These tissue and cell distribu-
tion studies demonstrate a much wider extrahepatic dispersion
of PRGB mRNA than PLG mRNA, and support the idea
that the two genes are expressed di¡erently.
3.4. Increased PRGB transcripts in cancer tissues
Since several transformed cell lines contained increased
amounts of the PRGB transcript as described above, we
next employed the RT-PCR assay to examine primary cancer
tissues obtained from cancer patients for the presence of the
PRGB transcript. PRGB transcripts appeared to be increased
in some cancer tissues when compared with their surrounding
normal tissues (Table 3), while in other cancer tissues they
remained unchanged. When the £uorescent intensity of the
ampli¢ed products was normalized to that of GAPDH, the
ratio of PRGB transcript in tumor tissue to that in normal
tissue ranged from 1.5^5.6 in breast carcinoma, gastric carci-
noma, colon carcinoma, bladder carcinoma and renal carci-
noma (Fig. 3), indicating that PRGB expression was increased
in these tissues. The levels of PLG mRNA, however, remained
unchanged (data not shown).
In order to substantiate these ¢ndings, we next carried out
semi-quantitative RT-PCR using a radiolabeled nucleotide.
Under experimental conditions, a linear relationship was ob-
served between the amounts of total RNA employed and the
radioactivity of these bands (Fig. 4, right: cancer, Robson’s
stage II renal cell carcinoma; normal, the surrounding normal
tissue). The relative ratio of PRGB/GAPDH was then calcu-
lated. Among the six samples, a renal cell carcinoma obtained
from patient 3 (stage IIIc by Robson’s classi¢cation) ex-
pressed PRGB most (PRGB/GAPDH ratio, 19.6), that from
patient 1 (stage I) least (1.4), and that from patient 2 (stage II)
yielded a level of expression between that of patient 3 and
patient 1 (4.0), when compared to the patients’ normal tissues
(Table 4). PRGB mRNA levels in normal kidney tissue were
fairly constant in these cases. Thus, the increase in PRGB
expression varied from one case to another even within the
same type of cancer. The reasons for this deviation in PRGB
expression are unknown at present. It is possible that the
variable PRGB expression is due to di¡erent stages of the
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Table 3
Detection of mRNAs for PRGB and PLG in neoplastic and normal tissues (a total of 26 neoplastic samples)
Tissue PRGB PLG
Tumor Normal Tumor Normal
Thyroid (adenoma) + + 3 3
Thymoma + + 3 3
Lung ca (small cell ca) + + 3 3
Lung ca (squamous cell ca) + + 3 3
Lung ca (adeno-ca) + + 3 3
Breast ca (papillotubular ca) + + 3 3
Breast ca (solid tubular ca) ++ + 3 3
Gastric ca (adenoma) + 3 3 3
Colon ca (adenoma) + þ 3 3
Ovarian ca (mucinous adenoma) + + 3 3
Bladder ca (transitional cell ca) + þ 3 3
Renal ca (renal cell ca) þ ^++ þ ^+ + +
Malignant lymphoma* 3 NA 3 NA
APL + NA 3 NA
CML + NA 3 NA
ca, carcinoma; NA, not available; *, di¡use lymphoblastic T-cell type; APL, acute promyelocytic leukemia; CML, chronic myelocytic leukemia
(blastic crisis). Each tissue was examined three times.
Fig. 3. Increased PRGB expression in cancer tissues. mRNA sam-
ples were extracted from cancers and their surrounding normal tis-
sues. The results for ¢ve selected samples are shown. Each tissue
was examined three times by the method.
T. Tateno, A. Ichinose/FEBS Letters 445 (1999) 31^3534
cancer’s progression. It was observed in this study that PRGB
expression in renal cell carcinoma increased indeed at rates
echoing the cancer’s own advancement as described above.
In contrast to renal cell carcinoma, among breast cancers
PRGB expression was high in a sample of solid tubular car-
cinoma (PRGB/GAPDH ratio, 10.3), but intermediate in two
samples of papillotubular carcinoma (4.1 and 2.3). All three
patients were in stage II. PRGB mRNA levels in the normal
breast tissue were constant (‘+’) in these cases. Therefore, it
may be said that the di¡erence in PRGB expression in breast
cancers is attributed to a di¡erence in cell types.
In summary, we found that PRGB expression varied widely
among di¡erent normal tissues and transformed human cell
lines. Furthermore, greatly increased PRGB expression was
observed in several cancer tissues obtained fresh from cancer
patients, when compared with surrounding normal tissues.
The pathophysiological function of PRGB, however, remains
unknown. The PAP domain of PLG interacts with the amino-
hexyl site of the PLG molecule [13] and is directly involved in
maintaining the activation-resistant conformation [14]. Thus,
the PAP domain plays an essential role in its activation and
¢brin binding, which results in the modulation of plasmin
generation. Accordingly, increased levels of the gene product
of PRGB composed of the PAP domain alone may a¡ect the
activation of PLG to plasmin, and may play a role in the
invasion and metastasis of cancer cells, such as extracellular
matrix destruction [3,15]. This assumption is analogous to the
fact that a 38 kDa fragment of PLG (K1^3), named angio-
statin, potently inhibits neovascularization, growth of tumors
and their metastases [16,17]. This hypothesis will be examined
in the future by the expression and characterization of re-
combinant PRGB in mammalian cells.
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Fig. 4. Semi-quantitative RT-PCR assay for the mRNAs of PRGB and GAPDH. A radioactive nucleotide ([K-35S]dCTP) was incorporated
into PCR products to estimate the amounts of mRNAs for both genes. Left: Four lanes (‘cancer’ tissue of Robson’s stage II renal cell carcino-
ma) on the left of both panels contain ampli¢ed products of diluted (1/8 or 1/16) samples from a cancer tissue. ‘Normal’ stands for a sample
from the surrounding normal tissue of the same patient. Right: Linear relationship between the amounts of total RNA employed and the £uo-
rescence intensity of the radioactive bands. Amounts of the ampli¢ed product roughly represent the amounts of mRNAs for PRGB (top) and
for GAPDH (bottom), respectively. Each tissue was examined three times.
Table 4
Semi-quantitation of mRNA for PRGB in cancer and normal tis-
sues
Tissue stage tumor/normal
Breast solid tubular ca stage II 10.3
Breast papillotubular ca-1 stage II 4.1
Breast papillotubular ca-2 stage II 2.3
Renal cell ca-1 stage I 1.4
Renal cell ca-2 stage II 4.0
Renal cell ca-3 stage IIIc 19.6
Each tissue was examined three times.
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